Healthcare Industry News: AIGISRx
News Release - April 21, 2010
TYRX Names Randy Mansfield as Vice President of MarketingMONMOUTH JUNCTION, N.J., April 21--(HSMN NewsFeed)--TYRX, Inc. announced today the appointment of former Medtronic-Kyphon executive Randy Mansfield as Vice President of Marketing effective immediately.
Mr. Mansfield brings over 20 years of sales, marketing, product commercialization, and general management experience in the medical device industry through numerous positions of increasing responsibility. His experience includes positions with Allergan Medical Optics, Bausch & Lomb Inc., and Medtronic Inc. Most recently, Mr. Mansfield served as Vice President of Marketing at Medtronic’s Kyphon business.
Mr. Mansfield began his medical device career with Allergan Medical Optics in 1989 where he was named Territory Manager of the Year for surgical product sales in 1993. At Bausch & Lomb Inc., his responsibilities included Cataract, Refractive, and Retinal Marketing, along with his last role as Vice President of Surgical Product Commercialization. Mr. Mansfield holds a BS and MBA degree from The University of Tennessee.
"Randy brings a very broad background of commercialization and market development skills and experience,” remarked Robert S. White, President and Chief Executive Officer. “Randy’s history in leading Kyphon’s marketing efforts will be invaluable as we continue to accelerate the market expansion of our AIGISRx® product lines.”
About TYRX, Inc.
TYRX, Inc., commercializes innovative, implantable combination drug/device products focused on infection control including the AIGISRx® Anti-Bacterial Envelope and the recently released AIGISRx® FS. AIGISRx® products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device (CRDM) related endocarditis, including "superbugs" or MRSA*.
Following commercial release in 2008, the AIGISRx® Envelope has been implanted in over 9,000 patients nationwide. The company estimates that approximately 2% of all U.S. CRMD patients in 2010 will receive an AIGISRx® product during their procedure.
TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center.
* Based upon preclinical in vitro and in vivo data. Data on file at TYRX and published in PACE 2009; 32(7) 898-907.
For more information, please visit www.TYRX.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.